Recent developments in bisphosphonates for patients with metastatic breast cancer

British Medical Journal

Volumn 330, Issue 7494, 2005, Pages 769-773

  Gainford, Mary C ^a   Dranitsaris, George ^a   Clemons, Mark ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT;

BONE METASTASIS; BREAST CANCER; CANCER INCIDENCE; CANCER PAIN; CANCER PATIENT; CANCER SURVIVAL; CLINICAL PRACTICE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DRUG EFFICACY; DRUG INDICATION; FEMALE; HEALTH CARE COST; HUMAN; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; BONE TUMOR; BREAST TUMOR; CONTROLLED CLINICAL TRIAL; FORECASTING; METASTASIS; RANDOMIZED CONTROLLED TRIAL;

ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; DIPHOSPHONATES; FEMALE; FORECASTING; HUMANS; RANDOMIZED CONTROLLED TRIALS;

EID: 16444369671     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.330.7494.769     Document Type: Review

References (29)

1. Jemal A, Tiwari R, Murray T, Ghafoor A, Samuels A, Ward E, et al. Cancer statistics 2004. CA Cancer J Clin 2004;54:8-29.
2. Body JJ, Diel IJ, Lichinitser MR, Kreuser ED, Dornoff W, Gorbunova VA, et al. On behalf of the MF 4625 Study Group. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 2003;14:1399-405.
3. Lipton A, Theriault R, Hortobagyi G, Simeone J, Knight R, Mellars K, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases-long term follow up of two randomized controlled trials. Cancer 2000;88:1082-90.
4. Hultborn R, Gundersen S, Ryden S, Holmberg E, Carstensen J, Wallgren UB, et al. Efficacy of pamidronate in breast cancer with bone metastases: a randomized, double blind placebo-controlled multicenter study. Anticancer Res 1999;19:3383-92.
5. Theriault R, Lipton A, Hortobagyi G, Leff R, Gluck S, Stewart J, et al. Pamidronate reduces the skeletal morbidity rate in women with advanced breast cancer and lytic bone lesions: A randomized controlled study. J Clin Oral 1999;17:846-54.
6. Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 1996;335:1785-91.
7. Conte PF, Latreílle J, Mauríac L, Calabresi F, Santos R, Campos D, et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational controlled trial. J Clin Oncol 1996;14:2552-9.
8. Tripathy D, Lichinitzer M, Lazarev A, MacLachlan SA, Apffelstaedt J, Budde M. On behalf of the MF 4434 Study Group. Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double blind, placebo-controlled trial. Ann Oncol 2004;15:743-50.
9. Body JJ, Diel IJ, Lichinitzer M, Lazarev A, Pecherstorfer M, Bell R, et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomized, placebo controlled phase III studies. Br J Cancer 2004;90:1133-7.
10. Tubiana-Hulin M, Beuzeboc P, Mauriac L, Barbet N, Frenay M, Monnier A, et al. Double blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases. Bull Cancer 2001;38:701-7.
11. Kristensen B, Ejlertsen B, Groenvold M, Hein S, Loft H, Mouridsen HT. Oral clodronate in breast cancer patients with bone metastases: a randomized study. J Intern Med 1999;246:67-74.
12. Paterson AHG, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S. Double blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993;11:59-65.
13. Van Holten-Verzantvoort ATM, Kroon HM, Bijvoet OLM, Cleton FJ, Beex LVAM, Blijham G, et al. Palliative pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol 1993;11:491-8.
14. Ross JR, Saunders Y, Edmonds PM, Patel S, Broadley KE, Johnston SRD. Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. BMJ 2003;327:469-75.
15. Pavlakis N, Stockier M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev 2004;4:CD00075320-100000000-02521.
16. Rosen LS, Gordon DH, Dugan W, Major P, Eisenberg PD, Provencher L, et al. Zolendronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 2004;100:36-43.
17. Wong R, Wiffen PJ. Bisphosphonates for the relief of pain secondary to bone metastases. Cochrane Database Syst Rev 2004;3:CD00075320-100000000-01585.
18. Clemons M, Verma S. Should oral bisphosphonates be standard of Care in women with early breast cancer? Breast Cancer Res Treat (in press).
19. Major P, Cook R. Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical end-points. Am J Clin Oncol 2002;25:s10-s18.
20. Anderson PK, Gill RD. Cox's regression model for counting processes: a large sample study. Ann Stat 1982;10:1100-20.
21. Plunkett TA, Smith P, Rubens RD, Risk of complications from bone metastases in breast cancer: implications for management. Eur J Cancer 2000;36:476-2.
22. Verma S, Kerr-Cresswell D, Dranitsaris G, Charbonneau F, Trudeau M, Yogendran G, et al. Bisphosphonate use for the management of breast cancer patients with bone metastases: a survey of Canadian medical oncologists. Support Care Cancer 2004;12:852-8.
23. LoRusso P. Analysis of skeletal related events in breast cancer and response to therapy. Semin Oncol 2001;28(suppl 11):22-7.
24. Hillner B, Ingle JN, Chlebowski RT, Gralow J, Vee GC, Janjan NA, et al. American Society Of Clinical Oncology 2003 Update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003;21:4042-57.
25. Clemons M, Enright K, Cesta A, Charbonneau F, Chow E, Warr D, et al. Do physicians follow systemic treatment and funding policy guidelines? A review of bisphosphonate use in patients with bone metastases from breast cancer. Can J Clin Pharmatol 2004;11:e168-e178.
26. Hillner B, Weeks JC, Desch CE, Smith T Pamidronate in prevention of bone complications in metastatic breast cancer: A cost effectiveness analysis. J Clin Oncol 2000;18:72-9.
27. Clamp A, Danson S, Nguyen H, Cole D, Clemons M. Assessment of therapeutic response in patients with metastatic bone disease. Lancet Oncol 2004;5:607-16.
28. Brown JE, Thomson CS, Ellis SP, Gutcher SA, Purohit OP, Coleman RE. Bone resorption predicts for skeletal complications in metastatic bone disease. Br J Cancer 2003;89:2031-7.
29. Brown J, Cook R, Major P, Lipton A, Saad F, Smith M, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer and other solid tumors. J Natl Cancer Inst 2005;97:59-69.